The firm will use the court-administered restructuring process to pursue strategic alternatives so it can continue developing vaccines and immunotherapies.
The firm is evaluating leniolisib, which is already approved and sold under the brand name Joenja for APDS, in certain primary immunodeficiencies with immune dysregulation.
After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.
The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.